Glenmark Pharmaceuticals , a prominent player in the Indian pharmaceutical sector, has issued a strong clarification regarding recent reports about certain drugs flagged by the Central Drugs Standard Control Organisation (CDSCO). The company has emphatically stated that the products in question are spurious and were not manufactured by Glenmark or any of its affiliates.

Clarification on Flagged Products

In a formal communication to the BSE Limited, Glenmark Pharmaceuticals addressed the news item that appeared in ' www.freepressjournal.in ' on April 28, 2025. The article, titled "CDSCO Flags 70 Drug Batches, Including Telma 40 And Eye Ointments, For Failing Quality Standards In March 2025 Tests," had raised concerns about the quality of certain pharmaceutical products.

Company's Stance

Harish Kuber, Company Secretary & Compliance Officer of Glenmark Pharmaceuticals, stated in the clarification:

"At the outset we wish to inform you that products referred to in the said News Article are spurious products which have not been manufactured by Glenmark Pharmaceuticals Limited or any of its affiliates."

The company further emphasized that they had already denied manufacturing these products and had clarified to FPJ (Free Press Journal) that the items in question were manufactured and sold by counterfeiters.

Regulatory Notifications

Glenmark highlighted that regulatory authorities, including the CDSCO and the Department of Health & Family Welfare, Government of West Bengal, have issued notifications confirming that the products in question are indeed spurious. This official recognition underscores the severity of the counterfeit issue and absolves Glenmark of any involvement in the production of these substandard drugs.

Proactive Measures Against Counterfeits

The pharmaceutical company assured stakeholders that it has been taking numerous steps to counter the menace of spurious and counterfeit products. These measures include:

• Implementing changes in packaging
• Strengthening the product supply chain
• Creating awareness to ensure the authenticity of its drugs

Commitment to Transparency

Glenmark reiterated its commitment to transparency, stating that they have been proactive in informing the Exchange about company events and will continue to do so. The company explained that since this was a counterfeit issue involving products not manufactured by Glenmark, it was not initially intimated to the exchanges.

This clarification from Glenmark Pharmaceuticals serves to address potential concerns about the quality and authenticity of its pharmaceutical products, reinforcing the company's commitment to maintaining high standards in the industry.

Glenmark Pharmaceuticals Ltd. , a prominent player in the Indian pharmaceutical sector, recently saw a notable block trade on the National Stock Exchange (NSE), catching the attention of market observers and investors alike.

Block Trade Details

A substantial block of Glenmark Pharmaceuticals shares changed hands in a single transaction on the NSE. The trade involved approximately 208,684 shares of the company, executed at a price of Rs. 1,350.60 per share. This significant transaction amounted to a total value of Rs. 28.18 crores.

Market Impact

Block trades of this magnitude often draw attention in the market as they can indicate strategic moves by large institutional investors or significant shareholders. While the identities of the buyer and seller in this transaction remain undisclosed, such trades can sometimes signal shifts in investor sentiment or portfolio adjustments by major market participants.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company headquartered in Mumbai, India. The company is known for its presence in various therapeutic areas, including:

• Dermatology
• Respiratory
• Oncology

Glenmark has a strong focus on research and development, with a growing portfolio of generic and branded medications.

Conclusion

This block trade comes at a time when the pharmaceutical sector continues to be of interest to investors, given its critical role in global healthcare and ongoing developments in drug research and manufacturing. Investors and market analysts will likely keep a close watch on Glenmark's stock performance and any potential disclosures that might shed light on this significant transaction.